Capelletto, Enrica <br/><br/>
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  08 2019 
 - 210-217 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2019.06.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carcinoma, Non-Small-Cell Lung--diagnosis<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--diagnosis<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Staging<br/>Prognosis<br/>Quality of Life<br/>Treatment Outcome